Skip to content

Negative Pressure Wound Therapy as a Drug Delivery System

Negative Pressure Wound Therapy as a Drug Delivery System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02463487
Enrollment
150
Registered
2015-06-04
Start date
2015-06-02
Completion date
2020-08-01
Last updated
2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcers

Brief summary

The investigators plan a randomized clinical trial of 150 patients with infected diabetes-related lower extremity wounds to compare the clinical and economic effectiveness of negative pressure wound therapy with continuous irrigation and negative pressure wound therapy without irrigation.

Detailed description

The investigators will enroll 150 patients from two centers: The University of Texas Southwestern University Hospital and Parkland Hospital. The investigators will screen and enroll patients with wounds in the inpatient setting. Patients will be randomized to receive traditional NPWT or NPWT with continuous irrigation while they are hospitalized. The average hospitalization for patients that receive NPWT is 13.3 days. Patients that do not have their wound surgically closed during hospitalization will be discharged with negative pressure wound therapy for up to a total of four weeks of therapy. After discharge from the hospital, subjects will be seen twice weekly by home health, and will be evaluated in clinic every 7 days (±7 days) up to a total of 16-week period or until 30 days after the wound heals. Study Procedures: Screening Procedures * Review and sign the Informed Consent and HIPAA Authorization * The study doctor will review the inclusion and exclusion criteria * Demographics (such as age, gender, race or ethnicity) * Physical exam * Sitting blood pressure and pulse * Height and weight * Collection of the medical and surgical history * Collection of the history of the wound * Wound assessment(s)/Debridement - various tests and measurements to assess the sensation (feeling) and circulation (blood flow) in the subject's feet and lower legs. None of these tests are invasive (using needles), uncomfortable or have risks greater than standard care. * Wound imaging - photographs and images of the subject's wound using acetate tracings, a digital camera and an ARANZ camera (a special type of camera that uses computer software to calculate the volume of the wound) * Hyperspectral imaging * Vascular/Neurological evaluation * Results of standard-of-care laboratory tests including a white blood cell count, blood chemistry (tests to see how well organs, such as the liver and kidneys are working), and blood glucose. Results of a serum pregnancy test (standard care for women of child-bearing potential as part of pre-op labs) will also be collected. About 2 tablespoons of blood will be drawn for these tests. * Collection of a list of the subject's current medications, including prescriptions, over-the-counter medications, supplements and herbals. This visit will last about 2 hours. If the subject qualifies for the study, they will participate in the following procedures: Group Assignment If the researchers believe the subject can take part in this study, s/he will be assigned randomly (like a flip of a coin) to receive one of the following therapies: * Negative Pressure Wound Therapy with Irrigation * Negative Pressure Wound Therapy without Irrigation The group is assigned randomly (like flipping a coin). The sponsor or researchers do not know in advance what group assignment each subject will receive. Neither the subject nor the researchers will be allowed to choose which group s/he is assigned to. Study Intervention The subject will receive either: * Cardinal Pro +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan®, or * Cardinal Pro (NPWT) Therapy (without Prontosan®) Assigned therapy will continue in the hospital until the physician determines that the wound is ready for closure. If the subject's wound is healing, study therapy will be discontinued and standard dressings will be applied. If surgical closure is needed, the subject will return to the Operating Room for a procedure to close the wound. If the wound is not ready for closure during the hospital stay, subjects will continue NPWT at home for the remainder of the 4 weeks of treatment. NPWT at home will be without irrigation (KCI VAC Via®). Procedures and Evaluations during the Research The study therapy will only be given while the subject is in the hospital. S/he will continue the therapy for up to 4 weeks or until the wound is closed. Once the therapy is stopped s/he will continue to be followed by the study doctor. After the subject is released from the hospital s/he will need to see the study doctor Every 7 days (±7 days). If the subject's wound does not heal before 56 days after his/her first surgery then s/he will no longer be taking part in the study. The study doctor will continue to check the wound. If the wound closes, s/he will see the study doctor 30 days later to have the closed wound checked. 12 Month Extension: After the end of the defined study period, the patients will be followed observationally by their electronic medical records for 12 months as it would not be feasible to ask them to return for an in-person evaluation as: patients have moved, no longer have correct contact information, as well as it would create a financial hardship on the patients to return for further visits. In order to more appropriately determine long term results from participation, a longer period of time of follow up is necessary. Related outcomes that we would like to follow over a 12-month duration are incidence of new foot ulcerations, re-ulceration of a previously healed foot wound, healing and time to healing of patients who took longer than the current study allows, duration of antibiotics received for foot infections, re-admissions to the hospital, need for subsequent surgery, amputation, loss of limb, and death. This expanded follow up period would provide valuable information to the long-term outcomes and complications of this high risk population and will help direct how future efforts may be better focused to reduce complications and improve outcomes.

Interventions

DEVICECardinal Pro +Simultaneous Irrigation (NPWTi)

NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®

DEVICECardinal Pro (NPWT) Therapy

NPWT 125 mm Hg continuous pressure with foam interface

Sponsors

Parkland Health and Hospital System
CollaboratorOTHER
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

Diagnosis of diabetes mellitus Men/women ≥21 years old Foot or ankle wounds sized 5 cm2 -100 cm2 ABI≥0.5 or toe pressures \>30 mmHg

Exclusion criteria

Active Charcot arthropathy Unable to use NPWT at home Untreated bone or soft tissue infection Unable to keep research appointments Active alcohol or substance abuse

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound16 weeksHow many wounds fully healed in 16 weeks. Healing defined as fully epithelialized skin with no drainage.

Secondary

MeasureTime frameDescription
Total Adverse Events of Participants16 WeeksTotal number of adverse events, including new foot ulcer formation, all-cause hospital readmission, and foot-related hospital readmission.
Number of Participants With Wound Dehiscence After Hospital Discharge16 weeksDehiscence is defined as any part of a surgically closed wound that failed to heal when sutures were removed.

Countries

United States

Participant flow

Recruitment details

The study population was comprised of patients who were admitted to hospital with a moderate or severe foot infection that required incision and drainage and parenteral antibiotics and for whom negative pressure wound therapy (NPWT) was indicated. Patients who fit the criteria for the study were then recruited.

Pre-assignment details

The patients underwent a screening exam including * evaluating sensory neuropathy with loss of protective sensation with a 10-gram monofilament * Vibration Perception Threshold Testing * ABI - ankle brachial index * SPP - skin perfusion pressure * Peripheral arterial disease (PAD) was defined as either ABI \<0.9 or SPP \<30 mm Hg.

Participants by arm

ArmCount
Cardinal Pro (NPWT) Therapy
Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation Cardinal Pro (NPWT) Therapy: NPWT 125 mm Hg continuous pressure with foam interface
75
Cardinal Pro + Irrigation (NPWTi)
Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation Cardinal Pro +Simultaneous Irrigation (NPWTi): NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
75
Total150

Baseline characteristics

CharacteristicCardinal Pro (NPWT) TherapyCardinal Pro + Irrigation (NPWTi)Total
Age, Continuous51.32 years
STANDARD_DEVIATION 8.22
49.07 years
STANDARD_DEVIATION 9.74
50.19 years
STANDARD_DEVIATION 9.05
Race/Ethnicity, Customized
African American
30 Participants30 Participants60 Participants
Race/Ethnicity, Customized
Caucasian
21 Participants18 Participants39 Participants
Race/Ethnicity, Customized
Hispanic
23 Participants26 Participants49 Participants
Race/Ethnicity, Customized
Native American
1 Participants1 Participants2 Participants
Sex: Female, Male
Female
17 Participants16 Participants33 Participants
Sex: Female, Male
Male
58 Participants59 Participants117 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 750 / 75
other
Total, other adverse events
27 / 7535 / 75
serious
Total, serious adverse events
39 / 7541 / 75

Outcome results

Primary

Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound

How many wounds fully healed in 16 weeks. Healing defined as fully epithelialized skin with no drainage.

Time frame: 16 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Cardinal Pro (NPWT) TherapyNumber of Participants Who Achieved Complete Healing or Coverage of the Study Wound44 Participants
Cardinal Pro + Irrigation (NPWTi)Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound45 Participants
p-value: 0.87t-test, 1 sided
Secondary

Number of Participants With Wound Dehiscence After Hospital Discharge

Dehiscence is defined as any part of a surgically closed wound that failed to heal when sutures were removed.

Time frame: 16 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Cardinal Pro (NPWT) TherapyNumber of Participants With Wound Dehiscence After Hospital Discharge46 Participants
Cardinal Pro + Irrigation (NPWTi)Number of Participants With Wound Dehiscence After Hospital Discharge40 Participants
p-value: 0.08t-test, 2 sided
Secondary

Total Adverse Events of Participants

Total number of adverse events, including new foot ulcer formation, all-cause hospital readmission, and foot-related hospital readmission.

Time frame: 16 Weeks

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cardinal Pro (NPWT) TherapyTotal Adverse Events of ParticipantsNew ulcer formation12 Participants
Cardinal Pro (NPWT) TherapyTotal Adverse Events of ParticipantsAll-cause readmission26 Participants
Cardinal Pro (NPWT) TherapyTotal Adverse Events of ParticipantsFoot-related readmission13 Participants
Cardinal Pro + Irrigation (NPWTi)Total Adverse Events of ParticipantsNew ulcer formation18 Participants
Cardinal Pro + Irrigation (NPWTi)Total Adverse Events of ParticipantsAll-cause readmission27 Participants
Cardinal Pro + Irrigation (NPWTi)Total Adverse Events of ParticipantsFoot-related readmission14 Participants

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026